CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...

TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by BITG.

After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit ...

PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

BioAge Labs, Inc. ( NASDAQ:BIOA ) investors will be delighted, with the company turning in some strong numbers with ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging ...

BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...